- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01176578
Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes (EPC-DM)
April 11, 2023 updated by: Steven J. Prior, Ph.D., Baltimore VA Medical Center
Exercise Training, CACs, and Vascular Function in Older Veterans With IGT (Impaired Glucose Tolerance)
The discovery of the role of endothelial progenitor cells (EPCs) and their involvement in the cardiovascular complications of type 2 diabetes (T2DM) would quickly have a significant impact on the millions of Americans who have T2DM.
This project is designed to 1) determine the mechanisms underlying EPC dysfunction in older, sedentary adults with T2DM compared those with normal glucose metabolism and impaired glucose metabolism, and 2) determine if aerobic exercise training is an efficacious therapy for EPC dysfunction in T2DM, and whether improvement in EPC number and function translates to improved endothelial function, increased capillarization, and improved glucose metabolism in T2DM.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
70
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Baltimore VA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 50-80
- Non-smoker
- If woman, postmenopausal >1 year
Exclusion Criteria:
- History of heart disease or stroke
- Cancer
- Poorly controlled hypertension or dyslipidemia
- Kidney or Liver diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T2DM
Type 2 Diabetes Mellitus
|
6 months of aerobic exercise training, 3 days per week
|
Experimental: IGT
Impaired Glucose Tolerance
|
6 months of aerobic exercise training, 3 days per week
|
Active Comparator: NGT
Normal Glucose Tolerance
|
6 months of aerobic exercise training, 3 days per week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Endothelial progenitor cell number
Time Frame: Baseline
|
Baseline
|
Endothelial progenitor cell number
Time Frame: 6-month
|
6-month
|
Skeletal muscle capillarization
Time Frame: Baseline
|
Baseline
|
Skeletal muscle capillarization
Time Frame: 6-month
|
6-month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cardiorespiratory Fitness
Time Frame: Baseline
|
Baseline
|
Cardiorespiratory Fitness
Time Frame: 6-month
|
6-month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2011
Primary Completion (Actual)
December 31, 2021
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
August 5, 2010
First Submitted That Met QC Criteria
August 5, 2010
First Posted (Estimate)
August 6, 2010
Study Record Updates
Last Update Posted (Actual)
April 13, 2023
Last Update Submitted That Met QC Criteria
April 11, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00047188
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
Clinical Trials on Aerobic Exercise Training
-
UNC Lineberger Comprehensive Cancer CenterCompletedStem Cell Transplantation, HematopoieticUnited States
-
National Taiwan University HospitalCompletedAtrial FibrillationTaiwan
-
Riphah International UniversityCompletedSpinal Cord InjuriesPakistan
-
University of HoustonTerminated
-
Istanbul University - Cerrahpasa (IUC)CompletedObstructive Sleep Apnea SyndromeTurkey
-
University of Alberta, Physical EducationCanadian Breast Cancer Research AllianceCompleted
-
Chang Gung Memorial HospitalCompleted
-
Chang Gung Memorial HospitalUnknownStroke Patients With Cognitive DeclineTaiwan
-
Federal University of UberlandiaSuspendedHypertension | Dyslipidemias | Multimorbidity | Multiple Chronic ConditionsBrazil
-
Parkwood Hospital, London, OntarioCanadian Institutes of Health Research (CIHR); University of Western Ontario...CompletedCognitive ImpairmentCanada